Cargando…
Using Extended-Release Injectable Aripiprazole for the Successful Treatment of Depressive Symptoms in Bipolar I Disorder
Extended-release injectable (ERI) aripiprazole is indicated for schizophrenia and maintenance monotherapy of bipolar I disorder. Clinical trials of aripiprazole failed to exhibit efficacy in the treatment of bipolar depression. It has been suggested that relatively high doses, rapid titration of dos...
Autores principales: | Kuo, Joseph, Lin, Shih-Ku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054796/ https://www.ncbi.nlm.nih.gov/pubmed/32148990 http://dx.doi.org/10.1155/2020/2615748 |
Ejemplares similares
-
Aripiprazole in the acute and maintenance phase of bipolar I disorder
por: Zupancic, Melanie, et al.
Publicado: (2012) -
Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole
por: Muzina, David J
Publicado: (2009) -
Concurrent, successful management of bipolar I disorder with comorbid alcohol dependence via aripiprazole long‐acting injection: A case report
por: Kurata, Tsutomu, et al.
Publicado: (2019) -
Aripiprazole Augmentation to Mood Stabilizers for Obsessive-Compulsive Symptoms in Bipolar Disorder
por: Di Salvo, Gabriele, et al.
Publicado: (2020) -
A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder
por: Citrome, Leslie
Publicado: (2006)